Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma
10.3760/cma.j.issn.0253-2727.2018.08.007
- VernacularTitle: COPADM方案治疗20例伯基特淋巴瘤患者远期疗效分析
- Author:
Dan YANG
1
;
Pu WANG
;
Jia CHEN
;
Caixia LI
;
Ying ZHANG
;
Xiaochen CHEN
;
Depei WU
Author Information
1. Department of Hematology, the First Affiliated Hospital of Suzhou University, Jiangsu Institute of Hematology, Suzhou 215006, China
- Publication Type:Journal Article
- Keywords:
Burkitt lymphoma;
Antineoplastic combined chemotherapy protocols;
Treatment outcome
- From:
Chinese Journal of Hematology
2018;39(8):645-649
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the long term efficacy of COPADM regimen in the treatment of Burkitt lymphoma (BL).
Methods:The clinical data of 39 patients with BL from April 2006 to June 2017 were retrospectively analyzed. According to different chemotherapy regimens, the patients were divided into COPADM group and control group.
Results:①Of 39 BL patients, 26 were male and 13 female. The median age was 30 (11-63) years old, including 25 younger than 40 and 14 older than 40. Among them, 33 patients were in stage Ⅲ-Ⅳ, 13 patients had B symptoms and 25 patients were IPI score≥3. ② Twenty patients treated with COPADM regimen (COPADM group), the 3 year overall survival (OS) and progression-free survival (PFS) were (83.5±2.6)% and (73.2±3.1)%, respectively. Nineteen patients in the control group had a 3-year OS and EFS of (47.4±2.4) % and (42.1±2.4) %, respectively. There were significant differences in OS and EFS between the two groups (all P<0.001). ③Of the 20 patients in COPADM group, 12 were younger patients (age≤40 years), their 3-year OS and EFS were (93.7±3.9)% and (83.3±5.4)%, respectively. The other 8 patients were older than 40 years old, and their 3-year OS and EFS were (48.3±8.5) %, (37.6±6.0) %, respectively. Both OS and EFS in younger patients was significantly better than older patients (P=0.004, P=0.045). ④ There were 24 patients treated with combination of Rituximab, their 3-year OS and EFS were (73.9±9.2)% and (69.9±9.6)%, respectively. The other 15 patients were treated without Rituximab, and their 3-year OS and EFS were (51.3±13.3) % and (38.1±12.9) %, respectively. There were significant differences in OS and EFS between the two groups (P=0.042, P=0.008).
Conclusion:COPADM regimen may improve the efficacy of BL. COPADM combined with Rituximab enables BL patients with greater benefit. The prognosis is significantly worse in patients older than 40 years old than in those less than 40 years old.
